A fixed-dose combination ophthalmic solution primarily indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Brimonidine is a selective alpha-2 adrenergic agonist that reduces aqueous humor production and increases uveoscleral outflow. Stabilized Oxychloro (Sodium Chlorite, stabilized) is a broad-spectrum antimicrobial and anti-inflammatory agent that helps manage blepharitis and ocular surface inflammation often associated with glaucoma therapy, improving tolerability and compliance.
Adult: One drop in the affected eye(s) twice daily, approximately 12 hours apart.
Note: Wash hands before use. Tilt head back, pull lower eyelid down to form a pouch. Instill one drop. Close eyes gently for 1-2 minutes, applying light pressure with finger at the inner corner of the eye (nasolacrimal occlusion) to minimize systemic absorption. Wait at least 5 minutes before instilling any other ophthalmic medication. Do not touch dropper tip to any surface to avoid contamination.
Brimonidine tartrate is a relatively selective alpha-2 adrenergic receptor agonist. Its primary mechanism for lowering IOP is dual: reduction of aqueous humor production by the ciliary body and increased uveoscleral outflow. Stabilized Oxychloro (Sodium Chlorite 0.005%) is an oxidative agent that, in solution, generates chlorine dioxide (ClO2). It exhibits broad-spectrum antimicrobial activity against bacteria, viruses, fungi, and Demodex mites. It also has anti-inflammatory properties, reducing pro-inflammatory cytokines and reactive oxygen species on the ocular surface and lid margin.
Pregnancy: Category B. Animal studies have shown no risk, but no adequate and well-controlled studies in pregnant women. Use only if clearly needed and potential benefit justifies potential risk to the fetus.
Driving: May cause blurred vision, dizziness, fatigue, or drowsiness. Patients should not drive or use machinery until they know how the medication affects them.
| Antihypertensives (Beta-blockers, ACE inhibitors, Diuretics) | Additive hypotensive effect, risk of severe hypotension/bradycardia. | Major |
| Cardiac Glycosides (Digoxin) | Increased risk of bradycardia. | Moderate |
| Tricyclic Antidepressants (Amitriptyline, Imipramine) | May antagonize the IOP-lowering effect of brimonidine. | Moderate |
| Monoamine Oxidase Inhibitors (Phenelzine, Tranylcypromine) | Potentiation of systemic alpha effects (hypertensive crisis); CONTRAINDICATED. | Major |
| CNS Depressants (Alcohol, Barbiturates, Opioids, Benzodiazepines) | Additive sedative effects. | Moderate |
| Other Topical Ophthalmic Agents (Beta-blockers, Prostaglandins, CAIs) | Additive IOP-lowering effect. Administer at least 5 minutes apart. | Minor |
Same composition (Brimonidine (0.1% w/v) + Stabilized Oxychloro (0.005% w/v)), different brands: